CRISPR diagnostics and gene-editing platform co-founded by Nobel laureate Jennifer Doudna
Mammoth was co-founded by CRISPR Nobel laureate Jennifer Doudna and discovered the Cas14 and CasΦ ultra-compact CRISPR systems suitable for in-vivo gene therapy. Pivoted from molecular diagnostics into CRISPR-based therapeutics. Partnership with Bayer for in-vivo gene editing applications.
Biotech📍 Brisbane, CAFounded 2018
Current Valuation
$1.0B
as of 2021-Q3
UNICORN
QL Price
$362.24M
-64% vs last round
QuantLogix's current estimate for Mammoth Biosciences, published 2026-10-08 — below the last disclosed round of $1.0B (2021-Q3).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$1.0B
2021-Q3
weight 0.03
Secondary market print
$326M
2026-06-27
weight 0.54
How this price has held up
No round has priced for Mammoth Biosciences since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-10-08 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Mammoth Biosciences, 2026-10-08 (67c751cc142f1915).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Mammoth Biosciences going public?
No. Mammoth Biosciences has no imminent IPO plans on record. It is still private.
What is Mammoth Biosciences' valuation in 2026?
Mammoth Biosciences is valued at $1.0B as of 2021-Q3, set by its Series D ($195M, Sep 2021). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Mammoth Biosciences filed an S-1?
No public S-1 is on file for Mammoth Biosciences.
Who are Mammoth Biosciences' investors?
Mammoth Biosciences' investors include Redmile Group, Foresite Capital, Senator Investment Group, Decheng Capital, Mayfield.
How much has Mammoth Biosciences raised?
Mammoth Biosciences has raised $379M in total, most recently a Series D of $195M in Sep 2021.
Is Mammoth Biosciences publicly traded — can you buy Mammoth Biosciences stock?
No. Mammoth Biosciences is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Mammoth Biosciences on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Trevor Martin
Founded
2018
HQ
Brisbane, CA
Employees
~150
Total Raised
$379M
Last Round
Series D — $195M (Sep 2021) · Lead: Redmile Group
IPO Status
no imminent plans
Fundraising Status
Series D · $195M · 5y 1mo ago
no imminent plansTotal raised $379M
Secondary Market
Implied price / share
$4.38
Last round price / share
$13.45
vs last round
-67.4%
Open interest
9
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series D
$195M
Sep 2021
Redmile Group
—
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Mammoth Biosciences — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-10-04. Re-checked weekly.
Talent Signal
Hiring trend
▼ Hiring downtrend
-67% vs 2026-08
Open roles
1
via lever
Product-build share
100%
engineering, research, product, design
Trajectory
tightening
heavy product build — 100% of open roles are product-building functions (engineering/research/product) — 1 of 1 open roles are research.
Open roles trending down; no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Senior Software Engineer I, Research Informatics
Counted from Mammoth Biosciences's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Redmile Group · Foresite Capital · Senator Investment Group · Decheng Capital · Mayfield
Products
DETECTR (CRISPR diagnostics)
Ultra-Compact CRISPR enzymes (Cas14, CasΦ)
Competitors
Caribou Biosciences · CRISPR Therapeutics · Intellia · Editas Medicine
BiotechCRISPRGene EditingDoudna
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2021-Q3. Refreshed quarterly.